Modulation of Cerebral Ischemia by Albumin

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 100 participants.

Also called NCT07415655

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 100 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07415655
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Czechia (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07415655. Randomized; no masking; primary purpose treatment. Start 2026-02-03 (actual); primary completion 2027-02-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Modulation of Cerebral Ischemia by Albumin
Acronym
MOZEG
Intervention (Drug)
Albumin infusion
Intervention (Drug)
Placebo Injection
Lead sponsor
University Hospital Hradec Kralove (class: other)

Record details

Record id
cardio:ct-nct07415655
Content hash
777a33e57085aaaed8454f5ef6b563c2fea297faefd9e69aab4ef72a45361bde